Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
Introduction This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM) in the USA.Research design and methods A retro...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMJ Publishing Group
2019-05-01
|
| Series: | BMJ Open Diabetes Research & Care |
| Acceso en liña: | https://drc.bmj.com/content/7/1/e000704.full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|